Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04835441 · ClinicalTrials.gov registry record · Phase 2
ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT04835441: Completed Phase 2 study, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
NCT04835441 is a Phase 2 study that has completed, run by Alpine Immune Sciences Inc, A Subsidiary of Vertex. The registered enrollment target is 76 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04835441, a Phase 2 study, has completed, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)
Interventions
- DRUG Placebo
- DRUG ALPN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 2 |
What the finished NCT04835441 record still lists
NCT04835441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04835441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04835441 about?
NCT04835441 is a clinical study titled "ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus". This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)
What is the current status of trial NCT04835441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2021-06-22. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT04835441?
The interventions under investigation include: Placebo (DRUG), ALPN-101 (DRUG).
Who is sponsoring clinical trial NCT04835441?
This trial is sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04835441's enrollment target sits among peer trials
76 893rd of 2000 higher than 1,101 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI